Study of DF6215 in Patients With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Solid Tumor, Adult, Solid Tumor Cancer
In brief
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered.
Key facts
- Study ID
- NCT06108479
- Run by
- Dragonfly Therapeutics
- People needed
- 35
- Starts
- 2023-11-28
- Expected to finish
- 2025-12-04
- Last updated by the study team
- 2026-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California, United States
- University of California Irvine Medical Center — Orange, California, United States
- University of California San Diego Moores Cancer Center — San Diego, California, United States
- Sarcoma Oncology Center — Santa Monica, California, United States
- Tampa General Hospital — Tampa, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- NYU Langone Health — New York, New York, United States
- Lifespan - Rhode Island Hospital — Providence, Rhode Island, United States
- SCRI Oncology Partners — Nashville, Tennessee, United States
- Cancer Research SA (CRSA) — Adelaide, South Australia, Australia
- Peninsula and South East Oncology Medical (PASO) — Frankston, Victoria, Australia
- Institut Bergonié — Bordeaux, France
- Centre Hospitalier Universitaire de Bordeaux — Bordeaux, France
- Centre Georges François Leclerc — Dijon, France
- CHU de Marseille - Hôpital de la Timone — Marseille, France
- Institut Paoli-Calmettes — Marseille, France
- Institut Curie — Paris, France
- Hôpital Lyon-Sud — Pierre-Bénite, France
- Centre Hospitalier Universitaire de Poitiers — Poitiers, France
- Institut de Cancérologie de l'Ouest - Saint-Herblain - Site René Gauducheau — Saint-Herblain, France
- Institut Universitaire du Cancer de Toulouse Oncopole — Toulouse, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.